Commitments and Contingencies - Legal Proceedings (Details) $ in Millions |
3 Months Ended | 6 Months Ended | |
|---|---|---|---|
|
Mar. 31, 2026
USD ($)
|
Jun. 30, 2026
USD ($)
lawsuit
|
Dec. 31, 2025
USD ($)
|
|
| Loss Contingencies [Line Items] | |||
| Finite-lived intangible assets, net | $ 109 | $ 45 | |
| Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) | |||
| Loss Contingencies [Line Items] | |||
| Litigation settlement liability | 950 | ||
| Amount awarded to other party | $ 876 | ||
| Loss contingency, estimate of possible loss | $ 74 | ||
| Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) | Maximum | |||
| Loss Contingencies [Line Items] | |||
| Litigation liability | 1,300 | ||
| Arbutus Biopharma Corporation (Arbutus) and Genevant Sciences GmbH (Genevant) | Intellectual Property | |||
| Loss Contingencies [Line Items] | |||
| Finite-lived intangible asset, useful life | 3 years | ||
| Finite-lived intangible assets, net | $ 66 | ||
| GlaxoSmithKline Biologicals | |||
| Loss Contingencies [Line Items] | |||
| Number of patent infringement cases | lawsuit | 2 |
| X | ||||||||||
- Definition Useful life of finite-lived intangible asset, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after accumulated amortization, of finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount awarded to other party in judgment or settlement of litigation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of loss contingency liability. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Reflects the estimated amount of loss from the specified contingency as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The total number of new claims filed pertaining to a loss contingency during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|